A Medical Device Daily Staff Report
OptiMedica (Sunnyvale, California) reported the closing of a $35 million growth round of financing. Proceeds will be used to continue the rapid global commercialization of the company's Catalys precision laser system for cataract surgery, support the development of system enhancements, and fuel a next-generation portfolio of additional products, OptiMedica said.
The round drew participation from all of OptiMedica's existing venture backers, which include Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital.
"OptiMedica has been committed to bringing the precision and safety benefits of femtosecond laser technology to cataract surgery since our founding in 2004. Today, we are literally standing at the forefront of a landscape shift in the field that, we believe, will ultimately make the laser the centerpiece of the procedure," said Mark Forchette, OptiMedica president/CEO. "Catalys has been shown in both clinical practice and clinical studies to deliver unparalleled precision and performance, with results and customer satisfaction that lead the industry. Our exceptional laser technology has enabled surgeons to achieve consistently excellent clinical results and explore a broad new area of innovation in the field. We are actively engaged in this exploration and look forward to a long future of scientific leadership that will continue to bring untold benefits to cataract surgeons and their patients."
OptiMedica's Catalys is FDA cleared and CE mark approved for performing every step of the laser cataract procedure. Since its international launch in November 2011 and its U.S. launch in February, the system has been installed at ophthalmic practices in 10 countries and used to perform more than 6,000 laser cataract procedures worldwide.
Catalys is a laser cataract surgery platform that combines a femtosecond laser, integrated 3-D optical coherence tomography imaging, and OptiMedica's pattern scanning technology in an ergonomic, easy-to-use system.
In other financing activity:
• bioMérieux (Paris) and Quanterix (Lexington, Massachusetts) reported a strategic agreement that gives bioMérieux worldwide exclusive rights to Quanterix's Simoa technology in clinical laboratories and for industrial applications. Quanterix will deliver a new instrument and consumables based on its Simoa technology. bioMérieux will develop ultra-sensitive and multiplex assays on the platform.
Quanterix has closed an $18.5 million Series C financing with participation from all existing investors, including ARCH Venture Partners, Bain Capital Ventures and Flagship Ventures, and joined by In-Q-Tel. bioMérieux has taken an initial $15 million equity stake in Quanterix.
Quanterix has invented an ultra-sensitive immunoassay technology, offering unprecedented assay performance with multiplex capability. Unlike the traditional analog-based methods of detecting proteins or biomarkers in a biological sample, Simoa is based on a digital approach that enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies, according to the company.
• Atossa Genetics (Seattle, Washington) reported closing its initial public offering of 800,000 shares of common stock for $5 a share. Dawson James Securities acted as the sole book-running manager and lead underwriter for this offering along with ViewTrade Securities and Paulson Investment Company.
Atossa Genetics sells diagnostic medical devices and tests designed to detect precursors to breast cancer.
• Seno Medical Technologies (San Antonio) raised $14.5 million in an equity round from 28 unnamed investors, according to a filing with the Securities and Exchange Commission.
The company is developing opto-acoustic imaging technology designed to locate cancerous tumors in breast tissue. According to the company, the technology uses laser light to slightly heat the tumor, which then emits an acoustic pressure wave that's detected by an array of sensors to pinpoint its location.
• Cynosure (Westford, Massachusetts) priced an underwritten registered public offering of 2.6 million shares of its class A common stock at $20.50 a share. The offering is expected to close around Nov. 21. Leerink Swann, the underwriter for the offering, has the option for up to 30 days to purchase up to an additional 240,000 shares from the company and up to an additional 240,000 shares from El.En at the public offering price.
Cynosure sells aesthetic treatment systems designed to be used to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis.